are you kidding me? 29% reduction in a disease state that has limited to no option except for transplant (which ends up badly eventually) and dialysis... that is on top of irbesartan 300mg use. A reduction of that nature would reduce the time to dialysis by approx 3-5 years
Fantastic news, chemocentryx failed this trial not long ago so now DXB is in the box seat for the FSGS market - which being a orphan disease is a potential blockbuster in itself.
Buckle up now for the DKD trial!
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-28
-
- There are more pages in this discussion • 259 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 21052 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |